It is a shame so many people have forgotten all the clinical results that have been released. The 40% response rate in Sheba 1 and the 50% bridge to transplant in the first stage of Sheba 2 trial. Oh and the 47 trials done by Lederle in 1800 patients including the Phase 3 breast cancer trial. Bisantrene is not a drug lacking clinical evidence of efficacy.
Ann: Race Strategic Update August 2023, page-288
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |